Clinical trial NCT06056011: Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018
Official title: TIMMY3 80601-2-56:2017 + A1 2018 Clinical Accuracy Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Febrile Illness
Lead sponsor: Baxter Healthcare Corporation
Sponsor class: INDUSTRY
First posted: 2023-09-28
Enrollment: 420
Sex: ALL
Minimum age (years): 1
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this document is to validate the clinical accuracy of the TIMMY3 thermometry module, integrated into host device CVSM, according to ISO 80601-2-56:2017 + A1 2018.

Detailed description: The purpose of this document is to validate the clinical accuracy of the TIMMY3 thermometry module, integrated into host device CVSM, according to 80601-2-56:2017 + A1 2018.

This study is designed to provide supporting documentation for the TIMMY3 module operating with SureTemp Plus algorithms. Testing will be performed with a production equivalent CVSM modified to use TIMMY3 (TIMMY3 investigational device), running the SureTemp Plus algorithms. The TIMMY3 module is intended to be integrated into additional Welch Allyn devices such as, but not limited to, the Connex Spot Monitor and Spot 4400. The process described below will be followed in accordance with the method called out in ISO 80601-2-56:2017 + A1:2018.

Eligibility criteria: Inclusion Criteria:

* Study subjects (person who is having their temperature taken) must meet the following criteria to participate in this study:

  * Subjects that are minors must provide assent to the clinical site's policy (if approved by Baxter) and/or the study sponsor's policy to participate in the study.
  * Subject or the legally authorized representative (LAR) must sign the informed consent form in order for the subject to participate.
  * Subject must be willing and able to comply with the study procedures.
  * Age: normal weight (full-term) newborn to adult
  * The study subject is in ambient temperature for at least 20 minutes prior to participating.
  * The study subject is able to have their temperature taken for up to six minutes for multiple rounds of temperatures per anatomical site.
  * The study subject is not physically or emotionally agitated/uncooperative.
  * The study subject or legal guardian speaks/understands fluent English.

Exclusion Criteria:

* Study subjects (person who is having their temperature taken) are excluded if they meet any of the below criteria. Any subject that withdraws from the study will be replaced.

  * The study subject has anatomical abnormalities that would affect temperature.
  * The study subject has any known contraindication to oral, axillary, or rectal temperature measurements.
  * The subject is not alert or unable to follow simple commands such as closing one's mouth completely around the probe if an oral reference temperature is being taken.
  * The study subject has consumed food or drink, or smoked, within the last 20 minutes. The subject may be included if they wait 20 minutes prior to taking oral temperature.
  * The study subject has engaged in strenuous or semi-strenuous activity within the last twenty minutes (i.e., running, weightlifting, etc.).
  * Subject has taken antipyretics (Aspirin, acetaminophen, ibuprofen) in the preceding 120 minutes.
  * Subjects has medical conditions such as inflammation at the MEASURING SITE (Barbiturates, thyroid preparations, antipsychotics, recent immunizations).
  * Neutropenic immunocompromised patients, in whom rectal manipulation may seed the blood with bacteria.

Note: The study subject will be excluded if the reference temperature does not stabilize after the 3 -5 minute monitoring time.

Primary outcomes:
measure: Validate the Clinical Accuracy of the Timmy3 thermometer algorithm
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: First Georgia Physicians Group
state: Georgia
city: Mankato
country: United States
facility: Mankato Clinic
state: Minnesota
city: Buffalo
country: United States
facility: John R. Oishei Children's Hospital
state: New York
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: Dallas
country: United States
facility: Forest Lane Pediatrics
state: Texas
Study officials:
affiliation: Baxter Healthcare Corporation
name: Eric Fernandez, M.D.
role: STUDY_DIRECTOR
References: